As discussed in Section 5, programmed cell death ligand 1 (PD-L1) plays an important role in immune checkpoints and has been approved as an ideal target for diagnosis and treatment in various tumor types, including NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.